Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blue Jet HealthcareBOM:544009 +1.74%62 PEG Ratio is 3.46 as of Aug. 02, 2026, which is 30% above its 10-year median of 2.66. GuruFocus rates BOM:544009 with a GF Score™ of 62/100 and a GF Value™ of ₹566.03 (Fairly Valued). The stock has 10 warning signs investors should review. Among 92 Biotechnology companies, Blue Jet Healthcare ranks worse than 71.74% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Blue Jet Healthcare's PEG Ratio or its related term are showing as below:
BOM:544009'
s PEG Ratio Range Over the Past 10 Years
Min: 1.98 Med: 2.66 Max: 3.46
Current: 3.46
During the past 6 years, Blue Jet Healthcare's highest PEG Ratio was 3.46. The lowest was 1.98. And the median was 2.66.
BOM:544009's PEG Ratio is ranked worse than 71.74% of 92
companies
in the Biotechnology industry
Industry Median: 1.915
vs BOM:544009: 3.46
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Blue Jet Healthcare (BOM:544009) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Blue Jet Healthcare PEG Ratio Related Terms
Blue Jet Healthcare PEG Ratio Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544009 vs VRTX, REGN, RVMD: PEG Ratio Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Blue Jet Healthcare (BOM:544009) has a PEG Ratio of 3.46 as of Aug. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Blue Jet Healthcare and its competitors. This is 30% above median its historical median of 2.66. Over the past decade, Blue Jet Healthcare's PEG Ratio has ranged from 1.98 to 3.46. According to the industry distribution chart, Blue Jet Healthcare ranks #66 out of 92 companies in the Biotechnology industry, placing it in the top 71.7%.
Is Blue Jet Healthcare's PEG Ratio too high?
Blue Jet Healthcare's current PEG Ratio of 3.46 is 30% above median its 10-year median of 2.66. Over the past 10 years, this metric has ranged from a low of 1.98 to a high of 3.46. The Biotechnology industry median PEG Ratio is 1.92. Blue Jet Healthcare's value of 3.46 is 80.7% above this industry median. Based on the distribution chart, Blue Jet Healthcare ranks #66 out of 92 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Blue Jet Healthcare has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #66 out of 92 companies for PEG Ratio. This places Blue Jet Healthcare in the lower half of its industry. The industry median PEG Ratio is 1.92. Blue Jet Healthcare's value of 3.46 is 80.7% above this benchmark. Historically, Blue Jet Healthcare's own PEG Ratio has ranged from 1.98 to 3.46 over the past decade. While the company's 10-year median is 2.66 vs. the industry median of 1.92, Blue Jet Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.92, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blue Jet Healthcare's current PEG Ratio of 3.46 is 80.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Blue Jet Healthcare and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blue Jet Healthcare's current PEG Ratio is 3.46, which is 30% above median its own 10-year median of 2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Fairly Valued. The stock's GF Value™ is ₹566.03, compared to a current price of ₹623.20 — trading 10.1% above its estimated fair value. The current PEG Ratio is 3.46, which is 30% above median its 10-year median of 2.66 and 80.7% above the Biotechnology industry median of 1.92. Blue Jet Healthcare's overall GF Score™ is 62/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current PEG Ratio is 3.46 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹623.20 is trading 10.1% above its estimated GF Value™ of ₹566.03.
GuruFocus considers Blue Jet Healthcare to be Fairly Valued.
Key valuation signals for BOM:544009:
PEG Ratio: 3.46 (30% above median its 10-year median of 2.66)
GF Value™: ₹566.03 vs. price of ₹623.20 (10.1% above fair value)
Industry Position: 80.7% above the Biotechnology median (#66 of 92)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
62GF Score
Get the complete analysis for BOM:544009
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
